Biohaven Ltd. (BHVN) – What Are Researchers Saying About This Stock?

Biohaven Ltd. (NYSE:BHVN) has received an average recommendation of “Moderate Buy” from the seventeen analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $18.69.

Several research analysts have issued reports on BHVN shares. Needham & Company LLC set a $11.00 price target on shares of Biohaven in a research report on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biohaven in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a research report on Friday, June 26th. Citigroup reiterated a “buy” rating on shares of Biohaven in a research note on Friday, September 18th. Finally, Morgan Stanley lifted their price target on shares of Biohaven from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th.

Institutional Investors Weigh In On Biohaven

Several hedge funds and other institutional investors have recently modified their holdings of BHVN. Opaleye Management Inc. bought a new stake in shares of Biohaven during the second quarter valued at approximately $1,159,000. BlueCrest Capital Management Ltd bought a new stake in shares of Biohaven during the second quarter worth $60,000. Engineers Gate Manager LP bought a new position in Biohaven in the 2nd quarter worth approximately $581,000. Integrated Wealth Concepts LLC lifted its position in Biohaven by 10.4% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 12,653 shares of the company’s stock valued at $188,000 after purchasing an additional 1,189 shares during the period. Finally, NewEdge Advisors LLC grew its stake in shares of Biohaven by 1,525.3% during the second quarter. NewEdge Advisors LLC now owns 16,659 shares of the company’s stock worth $248,000 after purchasing an additional 15,634 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Biohaven Trading Down 4.9%

Shares of NYSE:BHVN opened at $10.87 on Thursday. Biohaven has a twelve month low of $7.48 and a twelve month high of $18.57. The firm has a market cap of $1.64 billion, a P/E ratio of -2.34 and a beta of 1.35. The company has a 50 day moving average of $13.84 and a 200-day moving average of $12.56. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). As a group, analysts anticipate that Biohaven will post -3.33 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and immunological disorders. The company uses proprietary drug-development platforms to pursue treatments for conditions with significant unmet medical needs, including migraine, epilepsy, obsessive-compulsive disorder and other central nervous system diseases.

Biohaven’s pipeline has included small-molecule and biologic candidates such as troriluzole, an investigational therapy being studied in several neurological disorders, and other programs targeting ion channels, glutamate signaling and immune pathways.